兒童時期疾病資料雜誌 2005
益生菌用於治療異位性皮膚炎之效果:
隨機分組控制組試驗
澳大利亞西部大學 澳大利亞
此研究之目的為「 益生菌用於治療中度至嚴重性異位性皮膚炎之效果評估(年紀為6-18 個月大)」。 隨機分組之雙盲性、安慰劑控制試驗。56 位6~18個月大患有中度至嚴重異位性皮膚炎的嬰兒參與此項研究，其中有53位完成該項試驗。試驗者服用益生菌 F菌(L fermentum PCC) 菌數為3X109 或相同體積之安慰劑，每天服用兩次連續8週，最後依次評估門診為第16週後。結果之評估使用SCORAD標準遺傳性過敏症病患評估標準來評估異位性皮膚炎之嚴重度與病程。使用益生菌組其SCORAD指示標準比安慰劑組有顯著的降低。在第16週使用益生菌組中有92%的病患其SCORAD指示標準較安慰劑組佳。在試驗結束後，有54%，的病患其症狀改善至中度異位性皮膚炎，相較於安慰劑組只有30%改善。本試驗結果證實，益生菌F菌(L fermentum PCC)可以有效的改善中度至嚴重程度的異位性皮膚炎幼童症狀嚴重程度和病程。

期刊原文：
Arch Dis Child. 2005

Effects of probiotics on atopic dermatitis: a randomised controlled trial.
Weston S, Halbert AR, Richmond P, Prescott SL.

University of Western Australia, Australia.

OBJECTIVE: To investigate the effects of probiotics on moderate or severe atopic dermatitis (AD) in young children (6-18 months of age).

DESIGN: Randomised double blind placebo controlled trial.

SETTING: Perth, Western Australia.

PARTICIPANTS: Fifty six children aged 6-18 months with moderate or severe atopic dermatitis, 53 completed the study.

INTERVENTIONS: Supplementation with probiotic (3x10(9) L fermentum PCC(TM), [VRI BioMedical]), or equivalent volume of placebo, twice daily for eight weeks. A final assessment at sixteen weeks was performed.

MAIN OUTCOME MEASURES: Severity and extent of atopic dermatitis at the end of the study, as measured by the SCORAD index.

RESULTS: The reduction in SCORAD index over time was significant in the probiotic group (p=0.03) but not the placebo group. Significantly more children receiving probiotics (n=24, 92%) had a SCORAD index that was better than baseline at week 16 compared with the placebo group (n=17, 63%) (p=0.01). At the completion of the study more children in the probiotic group had mild AD (n=14, 54%) compared to placebo (n=8, 30%).

CONCLUSION: Supplementation with probiotic lactobacillus fermentum is beneficial in improving the extent and severity of atopic dermatitis in young children with moderate or severe disease